Ketoconazole has recently been shown to interfere with steroidogenesis in patients and rat in vitro systems. In this study we attempted to elucidate the site of inhibition in the adrenal gland. Although ketoconazole impaired adrenocorticotropic hormone stimulated cyclic (c)AMP production, dibutyrl cAMP addition did not bypass the steroidogenic blockade indicating that the critical ketoconazole-inhibited step was distal to cAMP. Addition of radiolabeled substrates to isolated adrenal cells and analysis of products by high performance liquid chromatography demonstrated a ketoconazole block between deoxycorticosterone (DOC) and corticosterone. This 11-hydroxylase step is carried out by a P450-dependent mitochondrial enzyme. No restriction of progesterone or pregnenolone conversion to DOC was detected, steps carried out by non-P450-dependent microsomal enzymes. Inhibition of cholesterol conversion to pregnenolone by mitochondrial fractions indicated a second block at the side chain cleavage step, another mitochondrial P450-dependent enzyme. Adrenal malate dehydrogenase, a non-P450-dependent mitochondrial enzyme was not inhibited while renal 24-hydroxylase, a P450-dependent mitochondrial enzyme in another organ, was blocked by ketoconazole. We conclude that ketoconazole may be a general inhibitor of mitochondrial P450 enzymes. This finding suggests that patients receiving ketoconazole be monitored for side effects relevant to P450 enzyme inhibition. Further, we raise the possibility that this drug action may be beneficially exploited in situations where inhibition of steroidogenesis is a therapeutic goal. A B S T R A C T Ketoconazole has recently been shown to interfere with steroidogenesis in patients and rat in vitro systems. In this study we attempted to elucidate the site of inhibition in the adrenal gland. Although ketoconazole impaired adrenocorticotropic hormone stimulated cyclic (c)AMP production, dibutyryl cAMP addition did not bypass the steroidogenic blockade indicating that the critical ketoconazole-inhibited step was distal to cAMP. Addition of radiolabeled substrates to isolated adrenal cells and analysis of products by high performance liquid chromatography demonstrated a ketoconazole block between deoxycorticosterone (DOC) and corticosterone. This 11-hydroxylase step is carried out by a P450-dependent mitochondrial enzyme. No restriction of progesterone or pregnenolone conversion to DOC was detected, steps carried out by non-P450-dependent microsomal enzymes. Inhibition of cholesterol conversion to pregnenolone by mitochondrial fractions indicated a second block at the side chain cleavage step, another mitochondrial P450-dependent enzyme. Adrenal malate dehydrogenase, a non-P450-dependent mitochondrial enzyme was not inhibited while renal 24-hydroxylase, a P450-dependent mitochondrial enzyme in another organ, was blocked by ketoconazole. We conclude that ketoconazole may be a general inhibitor of mitochondrial P450 enzymes. This finding suggests that patients receiving ketoconazole be monitored for side effects relevant to P450 enzyme inhibition. Further, we raise the possibility that this drug action may be beneficially exploited in situations where inhibition of steroidogenesis is a therapeutic goal.
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INTRODUCTION
Ketoconazole has been an efficacious antimycotic agent because of its minimal toxicity and its effectiveness after oral administration against a wide range of fungal pathogens (1) . However the appearance of gynecomastia in a few patients (2) was suggestive of a drug-hormone interaction. We and others recently showed that ketoconazole interfered with the production of adrenal (3) and gonadal steroids (4) both in patients and rat in vitro systems. These findings raised the possibility that ketoconazole, or a specifically designed analogue, could have additional utility as an inhibitor of steroidogenesis in the myriad clinical settings where reduction of steroid production would be useful, including Cushing's syndrome, hirsutism, and hormone-dependent cancers. We therefore pursued our studies of ketoconazole action to elucidate the step(s) in the steroidogenic pathway that were blocked by this antimycotic agent. The present paper demonstrates that ketoconazole inhibits adrenal mitochondrial P450-dependent enzymes. We detected inhibition of both the cholesterol side chain cleavage step as well as the 11-hydroxylation step. In addition, a kidney mitochondrial P450 enzyme, 25-hydroxy vitamin D-24-hydroxylase, was also blocked, suggesting that ketoconazole may have the general property of inhibiting P450-dependent enzymes. In the light of these findings additional side effects of ketoconazole relevant to P450 inhibition should be closely monitored. Moreover, we believe that studies to exploit this enzyme-blocking activity of ketoconazole in new clinical situations are now warranted. METHODS moved. Isolated adrenal cells were prepared by collagenase digestion as previously described (3). DNA was measured by the diphenylamine method (5) . Rats that were ether-stressed for 10 min to raise endogenous adrenocorticotropic hormone (ACTH)' were used to prepare adrenal mitochondria by the method described by Mason et al. (6) . Corticosterone and cyclic (c)AMP. Total cAMP (cells and medium combined) was extracted into 6% trichloroacetic acid, neutralized by the addition of CaCO3 (7), and measured by radioimmunoassay (Becton, Dickinson & Co., Orangeburg, NY). Corticosterone was extracted from the medium with methylene chloride and measured by radioimmunoassay as previously described (3) .
Steroidogenic studies. After 15 min of pretreatment of isolated cells or mitochondria with ketoconazole or vehicle (saline), radioactive substrates were added (0.5-1.0,Ci/ml) to begin the assay. Incubations were carried out for 5-120 min at 37°C under 95% 02:5% CO2. The reactions were stopped by centrifugation and radiolabeled products in the medium were extracted in 10 vol of chloroform/methanol, 2:1 (8 (10) .
RESULTS AND DISCUSSION The first experiments were designed to evaluate the possibility that ketoconazole interfered with the initial steps of ACTH-stimulated corticosterone production. We reasoned that measurement of cAMP generation would allow detection of an inhibitor action at the level of the ACTH receptor, the regulatory protein or the adenylate cyclase system. As shown in Table I , ketoconazole did partially inhibit cAMP generation. However, the reduction in cAMP was disproportionately less than the ketoconazole effect to inhibit corticosterone production (3) and therefore did not seem adequate to explain the steroidogenic block. This is especially true in the light of the excess cAMP that is known to be generated in relation to that required for steroidogenesis (11) . ' Abbreviations used in this paper: ACTH, adrenocorticotropic hormone; bt2cAMP, dibutyryl cAMP; cAMP, cyclic AMP; DOC, deoxycorticosterone; HPLC, high performance liquid chromatograph(y). To ascertain whether the cAMP inhibition played a role in the ketoconazole blockade of corticosterone production, we performed a dibutyryl cAMP (bt2cAMP) "bypass" experiment. As shown in Table II , ketoconazole inhibited corticosterone production despite bt2cAMP addition. The inability of bt2cAMP to bypass the ketoconazole blockade indicated that the impairment in steroidogenesis was distal to the cAMP production step.
We next sequentially evaluated the three major distal sterodogenic enzyme steps by making additions of the relevant radiolabeled substrates to isolated adrenal cells and analyzing the products by HPLC (Fig. 1) .
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Cultured pig kidney cells were treated with 13 nM 1,25(OH)2-vitamin D3 for 6 h, which induced a 26-fold rise in 24-hydroxylase activity. Cells were treated with vehicle or ketoconazole for 30 min before measurement of enzyme activity. This was assessed by the rate of conversion of [3H]25(OH)D3 substrate to 24,25(OH)2D3 product using HPLC with hexane/isopropanol 90:10 as the mobile phase.
